, Volume 1472, Issue 1, p 28
Date: 05 Oct 2013

Methylprednisolone/sulfasalazine

  • show all 0 hide

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Author Information

An event is serious (FDA MedWatch definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * requires intervention to prevent permanent impairment or damage

  • A 15-year-old boy developed DRESS after receiving sulfasalazine. During treatment with a methylprednisolone taper, his DRESS was exacerbated and he developed acute hepatitis.

    The boy, who had inflammatory bowel disease, developed bloody diarrhoea and was treated with sulfasalazine [route and dosage not stated]. After 1 week of therapy, he developed a cutaneous eruption on his extremities and his face.

    The boy's sulfasalazine was withdrawn 1 week after eruption onset. He presented to an emergency department 5 days later with worsening cutaneous eruption, lethargy, fever, and rigors. On admission, his temperature was 38.6°C. He had erythematous confluent plaques and papules which were most significant on his extremities, including his soles and palms. He also had